Assertio therapeutics agrees to merge with zyla life sciences

Press release - assertio therapeutics agrees to merge with zyla life sciences to create synergistic portfolio of neurology and non-opioid pain products.assertio therapeutics - sees combined company pro forma 2019 net product sales of approximately $128 million.expects to capture significant operating and product portfolio synergies upwards of $40 million,.assertio therapeutics - arthur higgins to become non-executive chairman and todd smith to be named president and ceo of combined company.assertio therapeutics- zyla stockholders will receive 2.5 shares of common stock of newly-formed holding co for each share of zyla common stock held.newly combined company will retain assertio name and trade on nasdaq under asrt ticker.
ASRT Ratings Summary
ASRT Quant Ranking